Irina Popa, MD
Hematology & Oncology · Omaha, NENPI 1649263542
Payments from drug & device makers
Across 123 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$257
- Pharmacyclics LLC, An Abbvie Company$173
- Merck$132
- AbbVie$122
- Seagen Inc.$122
- Genentech USA, Inc.$113
- plus $947 from 26 others
What the payments were for
- Food & beverage$1,74693%
- Education$925%
- Gifts$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 22 | $257 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $173 |
| Merck | 9 | $132 |
| AbbVie | 8 | $122 |
| Seagen Inc. | 8 | $122 |
| Genentech USA, Inc. | 18 | $113 |
| Novartis | 5 | $98 |
| Amgen | 4 | $87 |
| Lilly USA, LLC | 5 | $74 |
| Sanofi | 3 | $69 |
| Lexicon Pharmaceuticals, Inc. | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Johnson & Johnson | 3 | $49 |
| Array Biopharma Inc | 2 | $42 |
| Pfizer | 3 | $39 |
| Eisai Inc. | 2 | $37 |
| EMD Serono, Inc. | 2 | $32 |
| Bristol Myers Squibb | 2 | $31 |
| US Oncology Corporate, Inc. | 1 | $29 |
| Foundation Medicine, Inc. | 2 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Advanced Accelerator Applications | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Partner Therapeutics, Inc. | 1 | $16 |
| Novocure Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$1,867 in reported general payments places this provider in the 25th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 32 | $853 |
| Anastrozole | 18 | $327 |
| Ondansetron OdtOndansetron | 11 | $136 |
| Prochlorperazine Maleate | 12 | $105 |
| Allopurinol | 18 | $56 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$29.3M
- Ralph HaukeOmaha$12.1M
- Margaret BlockOmaha$8.3M
- Stefano TarantoloOmaha$3.7M
- Julie VoseOmaha$3.5M
- Robert BociekOmaha$3M
- Vijaya BhattOmaha$2.2M
- Mojtaba AkhtariOmaha$1.9M
- Mary WellsOmaha$1.6M
- Robert LangdonOmaha$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.